Appointment of Stephen M. Deitsch as new Chief Financial Officer
April 04, 2024 11:43 ET
|
ORGANOX LIMITED
OrganOx Appoints Stephen M. Deitsch, an experienced medtech finance leader with proven track record with IPOs, as new Chief Financial Officer.
Study Investigators Conclude RapidPulse™ Precise Cyclic Aspiration Is Highly Effective and Safe for Ischemic Stroke Large Vessel Occlusions
April 04, 2024 09:04 ET
|
RapidPulse, Inc
Study Investigators Conclude RapidPulse™ Precise Cyclic Aspiration Is Highly Effective and Safe for Ischemic Stroke Large Vessel Occlusions
Kardium har färdigställt patientrekryteringen inför ansökan om marknadsgodkännande
April 02, 2024 10:41 ET
|
Corline Biomedical AB
Kardium Inc. – en av Corlines kunder, som använder CHS™-ytan på sin Globe-kateter för behandling av hjärtarytmi – meddelar idag att man färdigställt patientrekryteringen i den registreringsgrundande...
Integer Schedules First Quarter 2024 Earnings Release and Conference Call for April 25, 2024
March 28, 2024 08:00 ET
|
Integer Holdings Corporation
PLANO, Texas, March 28, 2024 (GLOBE NEWSWIRE) -- Integer Holdings Corporation (NYSE:ITGR) announced today that it plans to release financial and operational results for first quarter 2024, at 7 a.m....
NeuroStar® Advanced Therapy Receives FDA Clearance as a First-Line Add-On Treatment for Adolescents with Depression
March 25, 2024 08:30 ET
|
Neuronetics
MALVERN, Pa., March 25, 2024 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM), a medical technology company focused on designing, developing, and marketing products that improve the quality of...
Sequel’s twiist™ Automated Insulin Delivery System Receives FDA 510(k) Clearance
March 18, 2024 07:05 ET
|
Sequel Med Tech
Sequel’s twiist™ automated insulin delivery system receives FDA 510(k) clearance. Significant advancements for people with people with Type 1 diabetes.
CytoSorbents Reports Fourth Quarter and Full Year 2023 Results
March 14, 2024 16:39 ET
|
CytoSorbents
CytoSorbents Reports Fourth Quarter and Full Year 2023 Results
Autonomix Completes First Three Patient Procedures in Human Clinical Trial Targeting Multi-Billion-Dollar Pancreatic Cancer Market
March 14, 2024 08:15 ET
|
Autonomix Medical, Inc.
First trial to ever evaluate radiofrequency (RF) ablation in a transvascular approach to reduce the pain associated with pancreatic cancer THE WOODLANDS, TX, March 14, 2024 (GLOBE NEWSWIRE) --...
electroCore Announces Fourth Quarter and Full Year 2023 Financial Results
March 13, 2024 16:05 ET
|
electroCore, Inc.
Record full year 2023 net sales of $16.0 million increased 87% over $8.6 million for the full year 2022 Company to host conference call and webcast today, March 13, 2024 at 4:30pm EST ROCKAWAY,...
electroCore to Participate in Upcoming Investor Conferences
March 12, 2024 08:00 ET
|
electroCore, Inc.
ROCKAWAY, N.J., March 12, 2024 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine and wellness company, announced today that the Company’s Chief Strategy...